Published in Haematologica on October 22, 2010
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood (2013) 1.44
CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection. J Virol (2013) 1.02
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One (2011) 1.00
Immunogenicity of an inactivated monovalent 2009 influenza A (H1N1) vaccine in patients who have cancer. Oncologist (2012) 0.90
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients. Haematologica (2011) 0.85
Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. Med Microbiol Immunol (2013) 0.83
Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis (2013) 0.83
Influenza and Pneumococcal Vaccination in Hematological Malignancies: a Systematic Review of Efficacy, Effectiveness, and Safety. Mediterr J Hematol Infect Dis (2016) 0.83
Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015). Hum Vaccin Immunother (2015) 0.81
A novel influenza A (H1N1) outbreak experience among residents of a long term-care facility in Saudi Arabia during 2010 seasonal flu circulation. Infect Dis Rep (2012) 0.78
A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation. Biol Blood Marrow Transplant (2012) 0.77
Vaccination of oncology patients: an effective tool and an opportunity not to be missed. Oncologist (2012) 0.76
Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy. Front Immunol (2016) 0.76
Low seroconversion after one dose of AS03-adjuvanted H1N1 pandemic influenza vaccine in solid-organ transplant recipients. Can J Infect Dis Med Microbiol (2013) 0.75
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol (2016) 0.75
Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant (2015) 0.75
Ibrutinib may impair serological responses to influenza vaccination. Haematologica (2017) 0.75
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 15.02
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet (2010) 12.43
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med (2009) 5.73
Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med (2009) 5.46
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A (2009) 4.47
T cell responses are better correlates of vaccine protection in the elderly. J Immunol (2006) 4.38
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet (2009) 3.98
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (2009) 3.97
Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis (2009) 3.12
Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Wkly Epidemiol Rec (2010) 2.10
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood (2004) 2.01
Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol (2010) 1.62
Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood (2002) 1.59
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol (2008) 1.44
Utility of influenza vaccination for oncology patients. J Clin Oncol (2010) 1.15
Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant (2008) 1.13
Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One (2008) 1.11
Clinical and immunologic predictors of influenza illness among vaccinated older adults. Vaccine (2010) 1.11
Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol (2005) 1.10
Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood (2006) 1.08
Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop (2009) 1.05
Comparison of single versus booster dose of influenza vaccination on humoral and cellular immune responses in older adults. Vaccine (2005) 1.01
Antibody response to a two-dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. Eur J Clin Microbiol Infect Dis (1993) 0.96
Influenza vaccination and chemotherapy: a shot in the dark? Support Care Cancer (2002) 0.95
Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Exp Hematol (2009) 0.94
Response to influenza virus vaccine in children receiving chemotherapy for malignancy. J Pediatr (1978) 0.87
Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol (2004) 0.87
Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.84
Cellular immune responses to recurring influenza strains have limited boosting ability and limited cross-reactivity to other strains. Clin Microbiol Infect (2010) 0.81
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Metadata matters: access to image data in the real world. J Cell Biol (2010) 12.49
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet (2010) 12.43
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood (2013) 8.00
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med (2003) 6.68
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med (2009) 5.73
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol (2008) 5.08
Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet (2004) 4.63
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol (2011) 4.32
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol (2010) 4.21
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
OMERO: flexible, model-driven data management for experimental biology. Nat Methods (2012) 3.72
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med (2002) 3.08
Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med (2013) 3.03
Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis (2010) 2.67
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood (2003) 2.60
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood (2008) 2.44
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 2.33
Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells (2006) 2.30
Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med (2008) 2.21
Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood (2013) 2.16
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol (2002) 2.14
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood (2008) 2.13
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A (2009) 2.08
Is imatinib still an acceptable first-line treatment for CML in chronic phase? Oncology (Williston Park) (2012) 2.07
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood (2008) 2.04
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood (2012) 2.01
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood (2007) 2.01
Unique localization of circulating tumor cells in patients with hepatic metastases. J Clin Oncol (2009) 1.99
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood (2010) 1.98
Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol (2007) 1.96
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood (2007) 1.92
A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses (2007) 1.92
The effects of imatinib on pregnancy outcome. Blood (2008) 1.92
Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis (2009) 1.88
Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? Blood (2003) 1.81
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol (2008) 1.76
Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica (2008) 1.72
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood (2009) 1.71
Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol (2004) 1.67
Left atrial sphericity: a new method to assess atrial remodeling. Impact on the outcome of atrial fibrillation ablation. J Cardiovasc Electrophysiol (2013) 1.67
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res (2010) 1.65
Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood (2012) 1.64
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood (2011) 1.63
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res (2011) 1.56
Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med (2007) 1.54
International standardisation of quantitative real-time RT-PCR for BCR-ABL. Leuk Res (2007) 1.54
Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.54
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood (2012) 1.54